29 Nov 2016

Two new methods will allow researchers world-wide to rapidly and accurately explore the changing role of genes as the cells develop into tissues such as liver, skin or heart, and discover how this contributes to health and disease.

Wellcome Trust Sanger Institute and University of Cambridge researchers have created sOPTiKO, a more efficient and controllable CRISPR genome editing platform. Today (29 November), in the journal Development, they describe how the freely available single-step system works in every cell in the body and at every stage of development. This new approach will aid researchers in developmental biology, tissue regeneration and cancer.

24 Nov 2016

Company founded on Institute technology goes from strength to strength.

Kymab is a company founded on genetic technologies developed at the Wellcome Trust Sanger Institute by Professor Allan Bradley. Its focus is discovering, developing and delivering new monoclonal antibody medicines to treat a variety of diseases.